Propiolactone

Summary

Propiolactone (CHEMBL1200627) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 72.06 Da · C3H4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200627
Name	Propiolactone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2365
ChEBI	CHEBI:49073
Molecular formula	C3H4O2
Molecular weight	72.06
InChIKey	VEZXCJBBBCKRPI-UHFFFAOYSA-N

SMILES: C1COC1=O

IUPAC name: oxetan-2-one

Also known as: .beta.-propiolactone, Beta-propiolactone, Betaprone, NSC-21626, Propiolactona, Propiolactone, SID17389751, PROPIOLACTONE, SID144204577

Patent coverage: 8,287 distinct patent families (20,542 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 20,541 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, Thyrotropin receptor, Aldehyde dehydrogenase 1A1, Cellular tumor antigen p53.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TP53	6.6	Potency	251.2	nM	CHEMBL_ACT_4830797

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).